What are biomarkers and how are they paving the way to personalized cancer treatment?
Over the last 50 years, cancer diagnosis and treatment have changed dramatically. We have moved beyond examining just the organ or tissue where cancer originates and develops—today, we can look at the features of cancer cells inside the tissue to get information and personalize the way we treat cancer. One of these features is known as a cancer biomarker.
Understanding what biomarkers are, how they’ve changed cancer care and when biomarker testing may be used can help you feel more informed if you or a loved one is being screened for cancer or has received a diagnosis.
What is a cancer biomarker?
Cancer biomarkers are like clues, telling us more about a patient’s cancer. They are biological markers—such as genes, proteins or hormones—that can help health care providers detect cancer and better understand its characteristics.
Cancer biomarkers can range from prostate-specific antigen (PSA) levels to mutations of the BRCA genes to hormone receptors on a tumor cell.
Two people may be diagnosed with cancer in the same part of the body, but certain features of their cancer cells can be different. Identifying those differences can help health care providers better understand the cancer and appropriate treatment.
How are biomarkers used?
Biomarkers can be used at different points in cancer prevention, detection and care. Biomarker testing can help assess a person’s cancer risk, screen for certain cancers, guide treatment decisions and monitor how well treatment is working. Here’s how:
- Before a diagnosis: A genetic counselor or other health care provider will assess the patient, considering their symptoms or their risk of cancer based on personal and family history. They may use a blood test to look for certain genes or proteins that increase cancer risk.
- During cancer screening: A provider can run blood tests to look for proteins that are present when there is cancer.
- Before or during treatment: Biomarkers are also used before or during treatment to personalize treatment based on tumor characteristics or to assess drug effectiveness during treatment.
Genetic changes, or mutations, are one type of biomarker. Some genetic changes can develop over a person’s lifetime because of certain exposures, such as sunlight, tobacco, some infections and radiation. Other genetic changes can be inherited from a parent. Both types of changes may increase the risk for certain cancers.
For example, inherited mutations in the BRCA1 Und BRCA2 genes can increase the risk of breast and ovarian cancers and, less commonly, prostate and pancreatic cancers. Testing for inherited genetic changes like these can help people better understand their cancer risk.
Biomarkers can also provide important information after a person has been diagnosed with cancer. Genetic changes found within a tumor can help health care providers better understand the cancer itself and, in some cases, identify treatments designed to target those changes and stop the cancer from growing.
These changes can be identified by testing tissue collected during a biopsy or by genomic sequencing, a type of test that can identify multiple genetic changes associated with cancer at once. By identifying these biomarkers, health care providers can learn more about what may be driving a cancer’s growth and make informed treatment decisions.
How has the use of biomarkers evolved over time?
Looking at breast cancer treatments provides a clear picture of how biomarker use has evolved.
In the late 1970s, breast cancer treatments were largely based on the size of the tumor and whether the cancer had spread to the lymph nodes. If the cancer had spread beyond the breast, it would require more intensive treatments.
During this time, treatment was often a one-size-fits-all approach—the same treatments were offered to all patients, even though only some of them had cancers that would respond positively.
That began to change when researchers discovered some breast cancer cells have proteins that cause the cancer to grow rapidly in response to estrogen (a type of hormone), also known as estrogen receptors, while others do not. Researchers began studying whether this difference could help determine which treatments would work best for each individual cancer case.
Clinical trials ultimately showed that hormone therapies, such as tamoxifen, only worked when breast cancer cells had estrogen receptors. Scientists then developed tests to look for these receptors in tumor tissue under a microscope. Today, testing for estrogen receptors is a standard part of breast cancer care, helping determine treatment recommendations.
Fast forward 25 years and researchers made another major discovery to make breast cancer treatment even more personalized. Researchers found that about 20% of breast cancers had unusually high levels of a protein called HER2, which was associated with a more aggressive form of breast cancer. Scientists then developed tests to identify high levels of HER2 in breast cancer tissue, which now helps determine who may benefit from treatments designed specifically to target the HER2 protein. HER2-Neu-associated breast cancer—what was once considered a particularly aggressive form of cancer—is now among the most curable of all breast cancers.
Biomarkers have changed the way we understand and treat cancer, giving health care providers more information about each person’s individual cancer and, in some cases, helping them choose treatments that are more likely to work. As research continues, biomarkers may play an even greater role in making cancer prevention and care more personalized.
Biomarkers can help you learn about your risk, screen for certain cancers, and choose the right treatment. Ask your health care provider whether biomarker testing may be appropriate and what the results could mean for your care.